My watch list
my.bionity.com  
Login  

28 Current news about the topic colitis ulcerosa

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
Why asbestos is so dangerous

09-Mar-2018

Long, pointed asbestos fibres induce chronic inflammation, which can lead to cancer. SNSF-funded researchers have found underlying mechanisms for this and hope their results will help prevent damage. The fact that asbestos causes cancer has been largely undisputed for nearly 50 years. Now, ...

more

image description
Immune cells that keep gut fungi under control

15-Jan-2018

Immune cells that process food and bacterial antigens in the intestines control the intestinal population of fungi, according to a new study from Weill Cornell Medicine scientists. Defects in the fungus-fighting abilities of these cells may contribute to some cases of Crohn's disease and other ...

more

Potent parasite protein - New therapeutic options for inflammatory bowel conditions?

24-Nov-2017

A single protein from a worm parasite may one day offer new therapeutic options for treating inflammatory bowel diseases like Crohn’s or Ulcerative Colitis, that avoid the potentially serious side effects of current immunosuppressant medications. The study demonstrates the discovery of a distinct ...

more

image description
Titanium dioxide nanoparticles can exacerbate colitis

20-Jul-2017

Titanium dioxide, one of the most-produced nanoparticles worldwide, is being used increasingly in foodstuffs. When intestinal cells absorb titanium dioxide particles, this leads to increased inflammation and damage to the intestinal mucosa in mice with colitis. Researchers at the University of ...

more

Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment

22-Mar-2016

Analysis reported clinical improvements with up to 152 weeks of vedolizumab treatment seen in patients with moderately to severely active ulcerative colitis Takeda Pharmaceutical Company Limited announced that the interim findings from the GEMINI Long-Term Safety (LTS) study were presented during ...

more

EMA recommends approval of a locally targeted treatment for ulcerative colitis

Entyvio (vedolizumab) offers a treatment option for patients who do not respond to standard therapies

27-Mar-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Entyvio (vedolizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis or Crohn’s disease, who have had an ...

more

Deadly immune ‘storm’ caused by emergent flu infections

03-Mar-2014

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus. Their findings, published in the online edition of the Proceedings of the ...

more

Beta-catenin alters T cells in lasting and harmful ways

Study helps explain chronic inflammation in autoimmunity and cancer

28-Feb-2014

Activation of beta-catenin, the primary mediator of the ubiquitous Wnt signaling pathway, alters the immune system in lasting and harmful ways, a team of Chicago-based researchers demonstrate in the issue of Science Translational Medicine. An increase in beta-catenin in certain types of T cells—a ...

more

Vedolizumab is an effective treatment for Crohn's disease and ulcerative colitis

27-Aug-2013

An international clinical trial led by Dr. Brian Feagan of Western University in London, Canada, has found that the investigational antibody vedolizumab is an effective treatment for those suffering from ulcerative colitis (UC) and Crohn's disease (CD) when other treatments have failed. The ...

more

EMA recommends approval of first two monoclonal antibody biosimilars

Recommendation marks extension of biosimilar concept to new product-class

03-Jul-2013

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting of marketing authorisations for the first two monoclonal antibody biosimilars. Remsima and Inflectra both contain the same known active substance, infliximab. In the application ...

more

Page 1 From 3
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE